ARTICLE | Company News
Bayer licenses anticoagulant from Isis
May 5, 2015 1:09 AM UTC
Bayer AG (Xetra:BAYN) gained exclusive, worldwide development and commercialization rights to anticoagulant candidate ISIS-FXIRx from Isis Pharmaceuticals Inc. (NASDAQ:ISIS) for $100 million up front.
Isis is eligible for a $55 million milestone after completing a Phase II trial of ISIS-FXIRx in patients with compromised kidney function, $320 million in additional milestones, and tiered royalties in the low to high 20% range. ...